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Background: The latent reservoir of HIV-1 in resting memory CD4+ T cells is a major barrier to curing HIV-1
infection. Eradication strategies involve reactivation of this latent reservoir; however, agents that reactivate
latent HIV-1 through non-speciﬁc T cell activation are toxic.
Methods: Using latently infected Bcl-2-transduced primary CD4+ T cells, we screened the MicroSource Spec-
trum library for compounds that reactivate latent HIV-1 without global Tcell activation. Based on the structures
of the initial hits, we assembled  50 derivatives from commercial sources and mostly by synthesis. The dose–
response relationships of these derivatives were established in a primary cell model. Activities were conﬁrmed
with another model of latency (J-Lat). Cellular toxicity and cytokine secretion were tested using freshly isolated
human CD4+ T cells.
Results: We identiﬁed two classes of quinolines that reactivate latent HIV-1. Class I compounds are the
Mannich adducts of 5-chloroquinolin-8-ol. Class II compounds are quinolin-8-yl carbamates. Most EC50
values were in the 0.5–10 mM range. HIV-1 reactivation ranged from 25% to 70% for anti-CD3+ anti-CD28
co-stimulation. All quinolin-8-ol derivatives that reactivate latent HIV-1 follow Lipinski’s Rule of Five, and
most follow the stricter rule of three for leads. After 48 h of treatment, none of the analogues induced detect-
able cytokine secretion in primary resting CD4+ T cells.
Conclusions: We discovered a group of quinolin-8-ol derivatives that can induce latent HIV-1 in a primary cell
model without causing global T cell activation. This work expands the number of latency-reversing agents and
provides new possible scaffolds for further drug development research.
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Introduction
Highly active antiretroviral therapy (HAART) can successfully
reduce plasma HIV-1 levels in infected individuals to below the
detection limit of clinical assays (,50 copies/mL) and reverse
disease progression.
1 However, the latent reservoir in resting
memory CD4+ T cells remains a major barrier to virus eradica-
tion. In these latently infected cells, integrated provirus
remains transcriptionally silent as long as the host cell remains
in a resting state.
2 The absence of viral proteins allows evasion
from immune surveillance, and HAART, which only targets repli-
cating virus, cannot eradicate latent HIV-1.
3 However, following
cellular activation, these latent HIV-1 genomes can be
transcribed and virus will be produced, leading to quick
rebound of viraemia upon the discontinuation of HAART. The
extreme stability of this latent reservoir makes life-long HAART
necessary. Given the potential for resistance, which might
result in HAART failure, and the toxicity and expense of life-long
HAART, elimination of the latent reservoir is an important goal.
# The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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398A widely discussed approach to eliminating this reservoir involves
reactivating latent HIV-1. Presumably cells harbouring latent
HIV-1 will die upon reactivation, due to viral cytopathic effects
or host cytolytic mechanisms. Even if this assumption is not
correct and additional strategies that kill productively infected
cells are needed, reactivation of HIV-1 gene expression is the im-
portant ﬁrst step.
Using different cell lines and primary cell models, several
groups have identiﬁed agents that reactivate latent HIV-1,
including the histone deacetylase (HDAC) inhibitors suberoylani-
lide hydroxamic acid (SAHA),
4 Trichostatin A,
5 valproic acid,
6 and
protein kinase C (PKC) activators prostratin
7 and bryostatin.
8
Because proliferating cell lines do not precisely mimic the quies-
cent state of the cells that harbour latent HIV-1 in vivo,w e
developed a latency model in primary resting human CD4+ T
cells transduced with the pro-survival gene bcl-2 and used this
model to screen for compounds that reverse latency.
9 Using
this system, we screened more than 5000 compounds from
the Johns Hopkins Drug Library and the MicroSource Spectrum
Library (MicroSource Discovery Inc, CN, USA), and reported two
latency-reversing agents, juglone (5-hydroxynaphthalene-1,4-
dione)
9 and disulﬁram.
10 Here we present a novel group of struc-
turally related compounds that reactivate latent HIV-1 in the
bcl-2-transduced primary CD4+ T cell model.
Materials and methods
Generation of bcl-2-transduced latently infected
primary CD41 T cells
This study was approved by the Johns Hopkins Institutional Review Board
(NA_00049895). Healthy adult blood donors provided informed consent
before enrolment. Latently infected cells were generated as described
by Yang et al.
9 Brieﬂy, primary CD4+ Tcells were transduced with pro-sur-
vival gene bcl-2, which allows the cells to return to the resting state upon
cytokine deprivation and ensures longer in vitro survival. Latency is estab-
lished by infecting these bcl-2-transduced cells with a recombinant HIV-1
vector carrying a destabilized green ﬂuorescent protein (GFP) gene in its
env ORF, then allowing the infected cells to return to a resting memory
state in a process that recapitulates the generation of resting memory
CD4+ T cells in vivo. Following reversal of latency, newly expressed GFP
can be detected by ﬂow cytometry.
Measurement of latency reversal
Latently infected bcl-2-transduced resting CD4+ T cells were plated at
5×10
4 cells/well, or J-Lat cells were plated at 2.5×10
4 cells/well, in
200 mL of RPMI 1640+ 10% FBS in U-bottomed 96-well plates, and
treated with stimuli for 24 h at 378C. Cells treated with 10 mg/L phorbol
12-myristate 13-acetate (PMA) and cells treated with 2.5 mg/L
anti-CD3 plus 1 mg/L anti-CD28 antibodies co-stimulation were used as
positive controls. Reactivation of latent HIV-1 was determined by quanti-
fying % GFP
+ cells using a FACS Calibur ﬂow cytometer (BD Biosciences,
USA). Results were normalized to the response to co-stimulation or
PMA treatment.
Measurement of toxicity
Freshly isolated primary CD4+ Tcells were treated with quinolin-8-ol deri-
vatives, or left untreated, for 24 h. Then cells were stained with propidium
iodide (PI), and the percentage of viable (PI negative) cells was measured
using ﬂow cytometry. Gating the viable cells in forward versus side
scatter plots produced very similar results.
Physical properties
Molecular weights, predicted octanol/water partition coefﬁcients
(miLogPs), and polar surface areas of hit compounds were calculated
by online tools at www.molinspiration.com.
Measurement of cytokine release
Primary resting CD4+ T cells were treated with active quinolin-8-ol deri-
vatives at their optimal concentration, or co-stimulation, or left untreated
for 48 h. Concentrations of cytokines in cell culture supernatant were
measured using a Meso Scale Human TH1/TH2 10-Plex Cytokine Array
(Meso Scale Discovery, Gaithersburg, MA, USA).
Results and discussion
During the screening of the MicroSource Spectrum library, three
compounds sharing the same quinoline core structure were iden-
tiﬁed as hits (Figure 1a). We designated quinolin-8-ol, which
represents the common core structure, as hit A. The other two
hits, 5-chloroquinolin-8-ol and 5-chloroquinolin-8-yl acetate,
were designated as hits C1 and E0, respectively. A basic quinoline
structure with position numbers is shown in Figure 1(b).
Figure 1(c) shows representative ﬂow cytometry data for these
compounds from the screening. In forward scatter–side scatter
(FCC-SCC) dot plots, cells treated with these hit compounds
retained the same small size of the untreated resting CD4+
cells, while the positive control stimulus PMA induced T cell acti-
vation and a signiﬁcant increase in cell size. The percentages of
GFP
+ cells (R2 in GFP-FL2 dot plots) induced by these hits were
not as high as those with PMA treatment, but still highly signiﬁ-
cant (P, 0.0001) compared with the untreated cells.
We assembled a library of 46 derivatives of quinolin-8-ol,
some from commercial sources but mostly by synthesis
(S. Bhat, J. S. Shim, F. Zhang, C. R. Chong and J. O. Liu, manuscript
submitted), and screened them using the primary cell model of
latency. Based on the screen results, we synthesized and
tested additional related compounds, and identiﬁed two
Figure 1. (a) Screening with a primary cell model of HIV-1 latency identiﬁed quinoline analogue hits. The results were normalized to the response to
10 mg/L PMA. (b) Basic quinoline structure. (c) A representative set of ﬂow cytometry data for untreated cells, cells treated with compound A, and
PMA-treated cells. The dot plots in the ﬁrst row are FSC-SSC plots. The GFP-FL2 dot plots in the second row (red) show viable cells gated in R1 in
FSC-SSC plots. Cells in R2 (GFP
+) are reactivated latently infected cells. The % GFP
+ cell is the number of cells in R2 divided by number of cells in
R1. All ﬂow data were collected under the same instrument settings. (d, e) Structures of two classes of analogues of the initial hits. (f, g) Dose–
response curves for these two classes of quinoline derivatives in the primary cell model. Cells were treated with quarter-log serial dilutions of each
compound for 24 h at 378C. Results were normalized to the response to co-stimulation. Data are means of duplicate samples from one of three
independent experiments using cells from different donors, all of which produced similar results.
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400Table 1. Summary of activity and physical properties of the compounds
Structure
Maximum
activation (% of
co-stimulation)
Concentration
required for
maximum
activation (mM)
EC50+SD
(mM)
Viable cells after
maximal
activation+SD
(%)
Viable cells
at
EC50+SD
(%)
Molecular
weight
(Da)
Octanol/
water
partition
coefﬁcient
(miLogP)
Polar
surface
area (A ˚2)
A
OH
N
26+6 18 4.4+1.2 93+49 3 +4 145.161 1.675 33.12
C1
OH
N
Cl 47+5 10 5.6+2.2 78+89 1 +8 179.606 2.608 33.12
C2
OH
N
N
O
Cl 55+4 1 0.56+0.1 87+10 96+3 278.739 2.186 45.592
C3
OH
N
N
N
Cl 37+3 5.6 2.5+0.2 92+79 7 +6 291.782 2.231 39.596
C4
OH
N
N
Cl 68+8 5.6 3.2+0.3 76+99 2 +6 276.767 3.248 36.358
D1
OH
N
N
Cl 39+4 5.6 3.3+0.2 71+88 8 +13 264.756 3.092 36.358
E0
O O
N
Cl 40+2 18 8.1+0.3 84+49 2 +4 221.643 2.379 39.197
E1
O O
NH
N
38+41 8 1 0 +0.5 85+13 91+8 230.267 3.746 51.224
E2
O O
NH
N
33+31 8 1 0 +0.3 88+89 2 +7 228.251 1.918 51.224
E3
O O
NH
N
37+8 32 13.5+1.5 89+89 4 +7 244.294 2.711 51.224
E4
O O
N
Cl
Cl
30+8 18 13.8+0.8 81+69 1 +3 256.088 2.985 39.197
Continued
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JACclasses of quinolines that reactivate latent HIV-1 (Figure 1d and
e). Class I compounds, designated C2–C4 and D1–D2, are the
Mannich adducts of 5-chloroquinolin-8-ol. Class II compounds,
designated E1–E5, are quinolin-8-yl carbamates, except E4,
which is a simple acetate. We examined the dose–response rela-
tionships for these derivatives and the original hits A, C1 and E0
in the primary cell model (Figure 1f and g). Some derivatives,
notably C2, induced activation at lower concentrations than
the original hits. C2 and C4 appeared to be the most potent, fol-
lowed by C3, D1, E5 and C1. D2 showed only minimal activity and
was excluded from further studies.
The reactivation activity in the primary cell model, toxicity,
and physical properties such as miLogP and polar surface area
of the compounds are summarized in Table 1. Most EC50
values are in the 0.5–10 mM range, comparable to disulﬁram in
the same model. Some patterns are apparent in the structure–
activity relationships. Among class I compounds (C2–C4), the
presence of morpholine or piperidine rings at position 7 of the
quinoline ring substantially lowers the concentration needed
for activation, and in some cases increases the level of activation.
D1, which is a Mannich adduct formed from an acyclic
amine, is not as potent as C2 or C4. The bis-Mannich adduct
D2 shows only minimal activity, as mentioned above. We also
found that adding a phenyl group to the b-carbon of the
Mannich adduct (for example compound C2 carrying such a
phenyl group) eliminated the activity, suggesting some steric
constraints in this region (data not shown). In addition, the pres-
ence of a chloro group at position 5 of the quinoline ring could
possibly contribute to lowering the concentration needed for
maximal activation. We also conﬁrmed the ability of these com-
pounds to reverse latency in another well-established model,
J-Lat cells (Table S1, available as Supplementary data at JAC
Online). Structure–activity relationships in J-Lat cells were very
similar to those observed in the primary cell model, except
that the concentrations needed for maximal activation and
EC50 values were about one half-log lower.
All quinolin-8-ol derivatives that reactivate latent HIV-1 follow
Lipinski’s Rule of Five. Each contains no more than four hydrogen
bond acceptors, and no more than a single hydrogen bond
donor. Molecular weights for all of the active analogues tested
are less than 300, and the calculated miLogPs are less than 4
(Table 1). These compounds also fulﬁl the criteria of Veber’s
Rules, as each has no more than ﬁve rotatable bonds and less
than 60 A ˚2 polar surface area (Table 1). Therefore these com-
pounds are drug-like, and most of them qualify for the stricter
‘rule of three’ for leads, and thus have the potential for chemical
modiﬁcations to improve activity and reduce toxicity while
retaining drug-like characteristics.
Since agents that induce latent HIV-1 through global T cell
activation would be too toxic for clinical use, mainly due to the
cytokines secreted, we tested whether these compounds
would induce cytokine secretion. None of the analogues
induced detectable secretion of any of a panel of 10 cytokines
(Table S2).
In conclusion, we discovered a group of quinolin-8-ol deriva-
tives that can induce latent HIV-1 in a primary cell model
without causing a substantial degree of T cell activation. This
work expands the number of known latency-reversing agents
and provides new scaffolds for drug development research.
Although it is not yet clear whether these compounds can reacti-
vate latent HIV-1 in vivo, it is possible that these compounds, or
their derivatives, may be useful in future eradication strategies,
either alone or in combination with other treatments.
Acknowledgements
We thank Shunyou Long and the Johns Hopkins University
High-throughput Center for helping us with the screening. We also
thank the Molinspiration Property Calculation Service for providing
predictions for physical properties.
Funding
This work was supported by National Institutes of Health (AI43222),
the Howard Hughes Medical Institute, and by an ARCHE grant from the
Foundation for AIDS Research.
Table 1. Continued
Structure
Maximum
activation (% of
co-stimulation)
Concentration
required for
maximum
activation (mM)
EC50+SD
(mM)
Viable cells after
maximal
activation+SD
(%)
Viable cells
at EC50+
SD (%)
Molecular
weight
(Da)
Octanol/
water
partition
coefﬁcient
(miLogP)
Polar
surface
area (A ˚2)
E5
O O
NH
N
Cl
Cl
35+3 5.6 3.9+0.3 88+99 6 +3 285.13 2.812 51.224
Summary of activity and physical properties of the compounds. Data are the mean+SD of three independent experiments using cells derived from
different donors. Cells were treated with quarter-log dilutions of the indicated stimuli for 24 h. Levels of activation were measured in latently infected
bcl-2-tranduced primary resting CD4+ Tcells as percentage of GFP
+ cells, normalized to co-stimulated cells. Toxicity was measured in freshly isolated
primary CD4+ T cells as percentage of viable cells, normalized to untreated cells.
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